Darunavir-d9 (CAS 1133378-37-6)
See product citations (1)
QUICK LINKS
Darunavir-d9 is a protease inhibitor that functions by binding to the active site of the HIV-1 protease enzyme. This binding prevents the enzyme from cleaving the viral polyproteins into functional proteins, ultimately inhibiting the maturation of infectious HIV-1 particles.Darunavir-d9′s mechanism of action involves forming strong interactions with the active site residues of the protease enzyme, disrupting its ability to catalyze the necessary cleavage reactions for viral replication. This interference with the protease enzyme′s function ultimately hinders the production of mature, infectious HIV-1 particles. Darunavir-d9′s mechanism of action at the molecular level involves specific interactions with the protease enzyme, leading to the inhibition of viral replication. Darunavir-D9′s functional role in experimental applications involves its ability to disrupt the protease enzyme′s activity, thereby impeding the production of infectious HIV-1 particles.
Darunavir-d9 (CAS 1133378-37-6) References
- A LC-tandem MS assay for the simultaneous measurement of new antiretroviral agents: Raltegravir, maraviroc, darunavir, and etravirine. | Fayet, A., et al. 2009. J Chromatogr B Analyt Technol Biomed Life Sci. 877: 1057-69. PMID: 19332396
- A validated high-performance liquid chromatography-ultraviolet method for quantification of the CCR5 inhibitor maraviroc in plasma of HIV-infected patients. | D'Avolio, A., et al. 2010. Ther Drug Monit. 32: 86-92. PMID: 20040898
- Application of a validated ultra performance liquid chromatography-tandem mass spectrometry method for the quantification of darunavir in human plasma for a bioequivalence study in Indian subjects. | Gupta, A., et al. 2011. J Chromatogr B Analyt Technol Biomed Life Sci. 879: 2443-53. PMID: 21788160
- Validation of simultaneous quantitative method of HIV protease inhibitors atazanavir, darunavir and ritonavir in human plasma by UPLC-MS/MS. | Mishra, T. and Shrivastav, PS. 2014. ScientificWorldJournal. 2014: 482693. PMID: 24587725
- Pre-clinical development of a combination microbicide vaginal ring containing dapivirine and darunavir. | Murphy, DJ., et al. 2014. J Antimicrob Chemother. 69: 2477-88. PMID: 24862093
- Population Pharmacokinetics Modeling of Unbound Efavirenz, Atazanavir, and Ritonavir in HIV-Infected Subjects With Aging Biomarkers. | Dumond, JB., et al. 2017. CPT Pharmacometrics Syst Pharmacol. 6: 128-135. PMID: 28032946
- Pharmacokinetic profile and safety of adjusted doses of darunavir/ritonavir with rifampicin in people living with HIV. | Ebrahim, I., et al. 2020. J Antimicrob Chemother. 75: 1019-1025. PMID: 31942627
- Pharmacokinetics and Immunological Effects of Romidepsin in Rhesus Macaques. | Kleinman, AJ., et al. 2020. Front Immunol. 11: 579158. PMID: 33362765
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Darunavir-d9, 1 mg | sc-218080 | 1 mg | $600.00 |